Terms: = Lymphoma AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
59 results:
1. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
[TBL] [Abstract] [Full Text] [Related]
2. shp2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
[TBL] [Abstract] [Full Text] [Related]
3. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
[TBL] [Abstract] [Full Text] [Related]
4. Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and shp2 inhibitors.
Berry MA; Bland AR; Ashton JC
Sci Rep; 2023 Jun; 13(1):10041. PubMed ID: 37339995
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical Study on the Relationship between Gene Mutation Profile and Prognosis in Pediatric Acute Lymphocyte Leukemia].
Chen Y; Qi SS; Ding LL; DU Y; Song N; Wang Z; Yang L; Sun M; Xiong H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):17-24. PubMed ID: 36765471
[TBL] [Abstract] [Full Text] [Related]
6. Spectrum and clinical features of gene mutations in Chinese pediatric acute lymphoblastic leukemia.
Shen D; Liu L; Xu X; Song H; Zhang J; Xu W; Zhao F; Liang J; Liao C; Wang Y; Xia T; Wang C; Lou F; Cao S; Qin J; Tang Y
BMC Pediatr; 2023 Feb; 23(1):62. PubMed ID: 36739388
[TBL] [Abstract] [Full Text] [Related]
7. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract] [Full Text] [Related]
8. [Pathological characteristics and clinical prognosis of nodular sclerosis grade 2 of classic Hodgkin's lymphoma].
Xue XM; Cao Z; Yuan T; Luo YY; Mu JL; Qin Y; Feng XL
Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):581-586. PubMed ID: 35754234
[No Abstract] [Full Text] [Related]
9. Imaging flow cytometry reveals a subset of TdT negative T-ALL blasts with very low forward scatter on conventional flow cytometry.
Rosenberg CA; Bill M; Maguire O; Petersen MA; Kjeldsen E; Hokland P; Ludvigsen M
Cytometry B Clin Cytom; 2022 Mar; 102(2):107-114. PubMed ID: 34648681
[TBL] [Abstract] [Full Text] [Related]
10. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract] [Full Text] [Related]
11. shp2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract] [Full Text] [Related]
12. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.
Koschut D; Ray D; Li Z; Giarin E; Groet J; Alić I; Kham SK; Chng WJ; Ariffin H; Weinstock DM; Yeoh AE; Basso G; Nižetić D
Oncogene; 2021 Jan; 40(4):746-762. PubMed ID: 33247204
[TBL] [Abstract] [Full Text] [Related]
13. Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.
Antić Ž; Yu J; Van Reijmersdal SV; Van Dijk A; Dekker L; Segerink WH; Sonneveld E; Fiocco M; Pieters R; Hoogerbrugge PM; Van Leeuwen FN; Van Kessel AG; Waanders E; Kuiper RP
Haematologica; 2021 Dec; 106(12):3046-3055. PubMed ID: 33147938
[TBL] [Abstract] [Full Text] [Related]
14.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
Alhumaid MS; Dasouki MJ; Ahmed SO; AbalKhail H; Hagos S; Wakil S; Hashmi SK
Acta Haematol; 2020; 143(6):583-593. PubMed ID: 32541138
[TBL] [Abstract] [Full Text] [Related]
16. Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer treatment?
Dempke WCM; Uciechowski P; Fenchel K; Chevassut T
Oncology; 2018; 95(5):257-269. PubMed ID: 29925063
[TBL] [Abstract] [Full Text] [Related]
17. shp2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
[TBL] [Abstract] [Full Text] [Related]
18. shp2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract] [Full Text] [Related]
19. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract] [Full Text] [Related]
20. Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL.
Kuo SH; Chen LT; Lin CW; Yeh KH; Shun CT; Tzeng YS; Liou JM; Wu MS; Hsu PN; Cheng AL
Blood; 2017 Jan; 129(2):188-198. PubMed ID: 27864293
[TBL] [Abstract] [Full Text] [Related]
[Next]
